Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: 360iResearch | PRODUCT CODE: 1595441

Cover Image

PUBLISHER: 360iResearch | PRODUCT CODE: 1595441

Polycystic Ovarian Syndrome Treatment Market by Drug Class (Anti-Depressants, Anti-Obesity, Insulin Sensitizing Agents), Surgery (Laparoscopic Ovarian Drilling, Ovarian Wedge Resection), Distribution Channel - Global Forecast 2025-2030

PUBLISHED:
PAGES: 188 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF, Excel & 1 Year Online Access (Single User License)
USD 3939
PDF, Excel & 1 Year Online Access (Enterprise User License)
USD 6969

Add to Cart

The Polycystic Ovarian Syndrome Treatment Market was valued at USD 3.25 billion in 2023, expected to reach USD 3.45 billion in 2024, and is projected to grow at a CAGR of 6.63%, to USD 5.09 billion by 2030.

The Polycystic Ovarian Syndrome (PCOS) treatment market encompasses a range of pharmaceuticals, nutraceuticals, and lifestyle interventions aimed at managing symptoms like menstrual irregularities, infertility, and metabolic issues. This market's necessity stems from the high prevalence of PCOS, affecting approximately 5-10% of women of reproductive age globally, with implications for both physical and mental health. Applications extend from hormonal birth control and insulin-sensitizing agents like metformin to surgical options, intended to alleviate symptoms and promote fertility. End-use primarily revolves around hospitals, fertility clinics, and individuals utilizing over-the-counter supplements and homeopathic remedies.

KEY MARKET STATISTICS
Base Year [2023] USD 3.25 billion
Estimated Year [2024] USD 3.45 billion
Forecast Year [2030] USD 5.09 billion
CAGR (%) 6.63%

Key factors influencing market growth include increasing awareness of PCOS among demographics due to enhanced diagnostic procedures and accessible healthcare information. Additionally, innovation in personalized medicine and the introduction of new treatment strategies present potential opportunities for pharmaceutical companies to address the unmet needs in symptom management. However, limitations like side effects of hormonal treatments, lack of definitive cures, high treatment costs, and socio-cultural obstacles in certain regions pose challenges to market expansion.

Areas ripe for innovation include the development of natural and bio-identical hormone therapies, advancements in ovulation-induction medications, and improved methods for weight management. There's also potential in leveraging digital health solutions, such as telemedicine and health apps, for enhanced patient engagement and compliance. The market is characterized by emerging trends in holistic treatment approaches, integrating modern medicine with lifestyle adjustments and alternative therapies. Businesses can capitalize on the growing consumer inclination towards personalized healthcare solutions by investing in research focused on genetic and metabolic drivers of PCOS. Ensuring affordability and accessibility, while creating awareness through campaigns and educational programs, can enable companies to capture a broader audience, offering robust avenues for business growth amid competition and evolving healthcare policies.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Polycystic Ovarian Syndrome Treatment Market

The Polycystic Ovarian Syndrome Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of PCOS worldwide
    • Increasing adoption of combination drugs
    • Rising organizational efforts to create awareness regarding PCOS
  • Market Restraints
    • Lack of approved drugs for PCOS
  • Market Opportunities
    • Ongoing research and development projects for drug development
    • Strategic alliances and investment for capacity expansion
  • Market Challenges
    • Side effects of PCOS drugs and treatment

Porter's Five Forces: A Strategic Tool for Navigating the Polycystic Ovarian Syndrome Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Polycystic Ovarian Syndrome Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Polycystic Ovarian Syndrome Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Polycystic Ovarian Syndrome Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Polycystic Ovarian Syndrome Treatment Market

A detailed market share analysis in the Polycystic Ovarian Syndrome Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Polycystic Ovarian Syndrome Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Polycystic Ovarian Syndrome Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Polycystic Ovarian Syndrome Treatment Market

A strategic analysis of the Polycystic Ovarian Syndrome Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Polycystic Ovarian Syndrome Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Ferring B.V., Johnson & Johnson Services, Inc., Lupin Limited, Merck & Co., Inc., Mylan N.V., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Polycystic Ovarian Syndrome Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Anti-Depressants, Anti-Obesity, Insulin Sensitizing Agents, and Oral Contraceptives.
  • Based on Surgery, market is studied across Laparoscopic Ovarian Drilling and Ovarian Wedge Resection.
  • Based on Distribution Channel, market is studied across Drug Stores, E-Commerce, Fertility Clinics, and Hospital Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-957C47F91255

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of PCOS worldwide
      • 5.1.1.2. Increasing adoption of combination drugs
      • 5.1.1.3. Rising organizational efforts to create awareness regarding PCOS
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of approved drugs for PCOS
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and development projects for drug development
      • 5.1.3.2. Strategic alliances and investment for capacity expansion
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects of PCOS drugs and treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Polycystic Ovarian Syndrome Treatment Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Anti-Depressants
  • 6.3. Anti-Obesity
  • 6.4. Insulin Sensitizing Agents
  • 6.5. Oral Contraceptives

7. Polycystic Ovarian Syndrome Treatment Market, by Surgery

  • 7.1. Introduction
  • 7.2. Laparoscopic Ovarian Drilling
  • 7.3. Ovarian Wedge Resection

8. Polycystic Ovarian Syndrome Treatment Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Drug Stores
  • 8.3. E-Commerce
  • 8.4. Fertility Clinics
  • 8.5. Hospital Pharmacies

9. Americas Polycystic Ovarian Syndrome Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Polycystic Ovarian Syndrome Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Polycystic Ovarian Syndrome Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. Bayer AG
  • 4. Bristol-Myers Squibb Company
  • 5. Eli Lilly and Company
  • 6. Ferring B.V.
  • 7. Johnson & Johnson Services, Inc.
  • 8. Lupin Limited
  • 9. Merck & Co., Inc.
  • 10. Mylan N.V.
  • 11. Novartis AG
  • 12. Pfizer Inc.
  • 13. Sanofi S.A.
  • 14. Takeda Pharmaceutical Company Limited
  • 15. Teva Pharmaceutical Industries Ltd.
Product Code: MRR-957C47F91255

LIST OF FIGURES

  • FIGURE 1. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-DEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-OBESITY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN SENSITIZING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY LAPAROSCOPIC OVARIAN DRILLING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY OVARIAN WEDGE RESECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!